This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. AZD4625 (AstraZeneca) is an oral inhibitor of KRASG12C being developed for the treatment of advanced solid malignancies. As indicated…
molecule
11 months ago ●
4 mins read
Context. JBJ-09-063 (Dana-Farber Cancer Institute) is an oral allosteric EGFR inhibitor currently in pre-clinical development for the treatment of EGFR…
molecule
11 months ago ●
6 mins read
Context. ABBV-318 (AbbVie) is a CNS-penetrating, oral inhibitor of Nav1.7/Nav1.8 being developed for pain treatment. Despite being a highly validated…
molecule
11 months ago ●
4 mins read
Context. Tenapanor (Ardelyx) is an oral, first-in-class Na+/H+ exchanger isoform 3 (NHE3) inhibitor approved by the FDA for irritable bowel…
molecule
11 months ago ●
5 mins read
Context. Lenrispodun (Intra-Cellular Therapies) is a phosphodiesterase (PDE) type 1 (PDE1) inhibitor being developed for CNS and non-CNS disorders, including…
molecule
11 months ago ●
6 mins read
Context. “Compound 41” (Vanderbilt University School of Medicine) is an oral WD40 Repeat Domain 5 (WDR5) inhibitor being developed for…
molecule
11 months ago ●
4 mins read
Load More
